Renhe Pharmacy Co

Renhe Pharmacy Co Debt/EBITDA

Total Debt to EBITDA Ratio of Renhe Pharmacy Co (000650.SZ) as of Oct 28, 2026.

Debt/EBITDA

0.00

YoY

-88.30%

Last updated:

Total Debt to EBITDA Ratio of Renhe Pharmacy Co is 2024 0.00 . Total Debt to EBITDA Ratio of Renhe Pharmacy Co was 2023 0.02 . It decreases by -88.30% lower compared to the previous year.

The Renhe Pharmacy Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
0.00 CNY
Jan 1, 2018
0.00 CNY
Jan 1, 2019
-0.08 CNY
Jan 1, 2020
0.07 CNY
Jan 1, 2021
0.03 CNY
Jan 1, 2022
0.03 CNY
Jan 1, 2023
0.02 CNY
Jan 1, 2024
0.00 CNY
The Renhe Pharmacy Co Debt/EBITDA history
YEARDebt/EBITDAYoY
0.00-88.30%
0.02-42.06%
0.03+6.24%
0.03-54.41%
0.07-183.06%
-0.08-37,651.18%
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renhe Pharmacy Co Stock analysis

What does Renhe Pharmacy Co do? Renhe Pharmacy Co., Ltd. generates revenue through the manufacturing and distribution of pharmaceutical products including capsules, granules, tablets, powder, injections, suppositories, and ointment. The company operates in the domestic market, focusing on medical industrial manufacturing and medical merchandising. Its primary customers are domestic healthcare providers and retail outlets purchasing health-related products for distribution or direct consumer use. The firm's product portfolio spans various dosage forms essential for medical treatment and patient care. The company's business model relies on both wholesale and retail channels within China, serving the domestic pharmaceutical market. Renhe Pharmacy's manufacturing segment produces a wide range of medication forms, while its merchandising division handles the sale of health-related products. This dual approach allows the company to capture value across the pharmaceutical supply chain from production to consumer. Renhe Pharmacy Co., Ltd. serves the Chinese domestic market exclusively, with its operations centered on medical industrial manufacturing and medical merchandising. The company's revenue streams are derived from the sale of its diverse product range to healthcare institutions, pharmacies, and consumers through its retail network. This integrated approach ensures consistent market presence and customer reach within its geographic focus. Renhe Pharmacy Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renhe Pharmacy Co stock

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Renhe Pharmacy Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Renhe Pharmacy Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Renhe Pharmacy Co

All Key Metrics — Renhe Pharmacy Co